Myocardial Infarction Drugs Market

Executive Summary

Myocardial Infarction Drugs Market was valued at US $1,938.89 million in 2021 and is projected to grow at 6.72% CAGR over the forecast period to reach US $2,864.39 million by 2027. Myocardial Infarction Drugs Market represented US $236.50 million opportunity over 2019-2021 and estimated to create US $925.50 million opportunity in 2027 over 2021.

Myocardial Infarction Drugs from Consainsights analyses the Myocardial Infarction Drugs Market in the Life Sciences industry over the forecast period to 2027.

Myocardial Infarction Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Myocardial Infarction Drugs segmentation includes Product Type, Distribution Channel, Region and Geography.

Based on the Product Type, the Myocardial Infarction Drugs analysis covers ANALGESICS, ANTIPLATELET AGENTS, VASODILATORS, THROMBOLYTICS, ANTI-THROMBOTIC AGENTS, GLYCOPROTEIN IIB/IIIA INHIBITORS, Β ADRENERGIC BLOCKERS, ANGIOTENSIN RECEPTOR BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS.

In Product Type segment, ANALGESICS segment has highest cagr growth of 5.95%.

Based on the Distribution Channel, the Myocardial Infarction Drugs analysis covers HOSPITAL PHARMACIES, HOSPITALS, DRUG STORES, ONLINE DRUG STORES.

In Distribution Channel segment, HOSPITAL PHARMACIES segment has highest cagr growth of 5.95%.

Based on the Region, the Myocardial Infarction Drugs analysis covers EUROPE, ASIA-PACIFIC, LAMEA.

In Region segment, EUROPE segment has highest cagr growth of 5.95%.

Based on the region, the Myocardial Infarction Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include ASTRAZENECA PLC, JANSSEN BIOTECH, INC., MERCK & CO. INC., SANOFI SA, PFIZER INC., BAYER AG, NOVARTIS INTERNATIONAL AG, DAIICHI SANKYO COMPANY LIMITED, BOEHRINGER INGELHEIM GMBH, ELI LILLY & COMPANY and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, ANALGESICS segment has the highest revenue of US $745.68 million and is expected to grow at CAGR of 5.95% by 2027 ANALGESICS segment has highest cagr growth of 5.95%.

ANALGESICS

ANALGESICS segment was valued at US $654.72 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $1,101.61 million by 2027. ANALGESICS segment represented US $90.95 million opportunity over 2019-2021 and estimated to create US $355.94 million opportunity in 2027 over 2021.

ANTIPLATELET AGENTS

ANTIPLATELET AGENTS segment was valued at US $411.02 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $691.57 million by 2027. ANTIPLATELET AGENTS segment represented US $57.10 million opportunity over 2019-2021 and estimated to create US $223.45 million opportunity in 2027 over 2021.

VASODILATORS

VASODILATORS segment was valued at US $251.10 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $422.49 million by 2027. VASODILATORS segment represented US $34.88 million opportunity over 2019-2021 and estimated to create US $136.51 million opportunity in 2027 over 2021.

THROMBOLYTICS

THROMBOLYTICS segment was valued at US $148.76 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $250.30 million by 2027. THROMBOLYTICS segment represented US $20.67 million opportunity over 2019-2021 and estimated to create US $80.87 million opportunity in 2027 over 2021.

ANTI-THROMBOTIC AGENTS

ANTI-THROMBOTIC AGENTS segment was valued at US $94.10 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $158.33 million by 2027. ANTI-THROMBOTIC AGENTS segment represented US $13.07 million opportunity over 2019-2021 and estimated to create US $51.16 million opportunity in 2027 over 2021.

GLYCOPROTEIN IIB/IIIA INHIBITORS

GLYCOPROTEIN IIB/IIIA INHIBITORS segment was valued at US $62.95 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $105.92 million by 2027. GLYCOPROTEIN IIB/IIIA INHIBITORS segment represented US $8.75 million opportunity over 2019-2021 and estimated to create US $34.22 million opportunity in 2027 over 2021.

Β ADRENERGIC BLOCKERS

Β ADRENERGIC BLOCKERS segment was valued at US $24.37 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $41.00 million by 2027. Β ADRENERGIC BLOCKERS segment represented US $3.38 million opportunity over 2019-2021 and estimated to create US $13.25 million opportunity in 2027 over 2021.

ANGIOTENSIN RECEPTOR BLOCKERS

ANGIOTENSIN RECEPTOR BLOCKERS segment was valued at US $32.78 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $55.15 million by 2027. ANGIOTENSIN RECEPTOR BLOCKERS segment represented US $4.55 million opportunity over 2019-2021 and estimated to create US $17.82 million opportunity in 2027 over 2021.

ANGIOTENSIN CONVERTING ENZYME INHIBITORS

ANGIOTENSIN CONVERTING ENZYME INHIBITORS segment was valued at US $22.60 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $38.03 million by 2027. ANGIOTENSIN CONVERTING ENZYME INHIBITORS segment represented US $3.14 million opportunity over 2019-2021 and estimated to create US $12.29 million opportunity in 2027 over 2021.

Distribution Channel

Introduction

In 2021, HOSPITAL PHARMACIES segment has the highest revenue of US $823.00 million and is expected to grow at CAGR of 5.95% by 2027 HOSPITAL PHARMACIES segment has highest cagr growth of 5.95%.

HOSPITAL PHARMACIES

HOSPITAL PHARMACIES segment was valued at US $722.61 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $1,215.84 million by 2027. HOSPITAL PHARMACIES segment represented US $100.39 million opportunity over 2019-2021 and estimated to create US $392.85 million opportunity in 2027 over 2021.

HOSPITALS

HOSPITALS segment was valued at US $556.16 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $935.77 million by 2027. HOSPITALS segment represented US $77.26 million opportunity over 2019-2021 and estimated to create US $302.35 million opportunity in 2027 over 2021.

DRUG STORES

DRUG STORES segment was valued at US $416.67 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $701.07 million by 2027. DRUG STORES segment represented US $57.88 million opportunity over 2019-2021 and estimated to create US $226.52 million opportunity in 2027 over 2021.

ONLINE DRUG STORES

ONLINE DRUG STORES segment was valued at US $6.96 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $11.71 million by 2027. ONLINE DRUG STORES segment represented US $0.97 million opportunity over 2019-2021 and estimated to create US $3.78 million opportunity in 2027 over 2021.

Region

Introduction

In 2021, EUROPE segment has the highest revenue of US $951.38 million and is expected to grow at CAGR of 5.95% by 2027 EUROPE segment has highest cagr growth of 5.95%.

EUROPE

EUROPE segment was valued at US $835.34 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $1,405.51 million by 2027. EUROPE segment represented US $116.04 million opportunity over 2019-2021 and estimated to create US $454.13 million opportunity in 2027 over 2021.

ASIA-PACIFIC

ASIA-PACIFIC segment was valued at US $667.33 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $1,122.82 million by 2027. ASIA-PACIFIC segment represented US $92.70 million opportunity over 2019-2021 and estimated to create US $362.79 million opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $199.73 million in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $336.06 million by 2027. LAMEA segment represented US $27.75 million opportunity over 2019-2021 and estimated to create US $108.58 million opportunity in 2027 over 2021.